TGFB1 and triple-negative breast carcinoma: TGF-β pathway inhibitors, including ligand traps and receptor kinase blockers, are being evaluated in combination with immune checkpoint inhibitors to overcome immune exclusion phenotypes in triple-negative breast cancer [38].